New Method for Transcytosis Pathway and Ligand Discovery

描述（由申请人提供）：目前口服给药的方法 大分子和其它不易被肠吸收的药物不能提供 足够的口服生物利用度。因此，新的肠道转运途径 必须识别更大量的化合物。不幸的是，目前 途径鉴定的方法是不充分的。XenoPort将解决此问题 通过开发在噬菌体上展示合成分子的新方法， 颗粒，充分利用精致的灵敏度和多功能性的 用于展示分子文库的噬菌体。这些库将用于 筛选指导最活跃的转胞吞途径的受体配体 通过肠上皮细胞，使商业化的发展， 技术平台适用于所有治疗中的各种化合物 地区第一阶段研究将通过合成， 表征1000个成员的化学文库并将其连接至噬菌体，和 选择活性化合物。第二阶段将开发一个高度多样化， 100，000个成员的文库，也将通过选择生物学 活性合成分子该技术将通过内部 产品开发和战略合作伙伴关系。 拟议商业应用：不可用

DESCRIPTION (provided by applicant): Current methods for oral delivery of macromolecular and other drugs poorly absorbed by the intestine do not provide adequate oral bio-availability. Thus, new intestinal pathways to transport larger quantities of compound must be identified. Unfortunately, current methods of pathway identification are inadequate. XenoPort will address this problem by developing a new method for displaying synthetic molecules on phage particles to fully exploit the exquisite sensitivity and versatility of the phage for display of molecular libraries. These libraries then will be used to screen for ligands to receptors directing the most active transcytosis pathways through the intestinal epithelium, enabling development of a commercial-ready technology platform adaptable to a wide variety of compounds in all therapeutic areas. Phase I studies will demonstrate feasibility by synthesizing, characterizing, and attaching a 1000-member chemical library to phage, and selecting for active compounds. Phase II will develop a highly diverse, 100,000-member library that also will be validated by selection of biologically active, synthetic molecules. The technology will be commercialized via internal product development and strategic partnerships. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE